Research Article Details
| Article ID: | A03842 |
| PMID: | 33851592 |
| Source: | Wiad Lek |
| Title: | THE ROLE OF ZONULIN IN THE DEVELOPMENT OF LIVER FIBROSIS IN OBESE ADOLESCENTS. |
| Abstract: | OBJECTIVE: The aim: To study the relationship between zonulin level and PNFI (pediatric non-alcoholic fatty liver disease fibrosis index) in obese adolescents. PATIENTS AND METHODS: Material and methods: A total of fifty-nine obese subjects aged 12-17 years and thirteen healthy subjects were included in the study. Clinical, biochemical parameters, including serum zonulin, were examined and abdominal ultrasound examination was performed. For the assessment of liver fibrosis PNFI was calculated. RESULTS: Results: According to ultrasound examination 71,2% of obese adolescents had non-alcoholic fatty liver disease (NAFLD). Calculation of PNFI showed that 25,4% of obese subjects had fibrotic processes in the liver. Obese adolescents had significantly higher zonulin levels compared to normal weight peers - 91,8±3,1 vs 15,9±5,1 respectively (р<0,01). A significant positive correlation was established between zonulin levels and such parameters as body mass index, waist circumference / height ratio, triglycerides, very low-density lipoprotein cholesterol, insulin, homeostasis model assessment of insulin resistance, PNFI (p<0,05). CONCLUSION: Conclusions: The level of zonulin increases with an increase of the index for evaluating liver fibrosis (PNFI) in obese adolescents. This may indicate the effect of the state of the intestinal barrier on the development and progression of obesity-related liver pathology, namely NAFLD, in obese adolescents. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |